New combo therapy targets high-risk MDS in early trial

NCT ID NCT07387354

Not yet recruiting Disease control Sponsor: Thomas Jefferson University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new two-drug combination (pacritinib plus azacitidine) for people with moderate to very high risk myelodysplastic syndrome (MDS), a bone marrow disorder. The first part finds the safest dose of pacritinib, and the second part checks how well the combination works. About 25 adults will take part. The goal is to control the disease and improve blood counts.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BONE MARROW DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bone marrow disorder hematologic disorder myelodysplastic syndrome Myelodysplastic Syndromes Myeloproliferative Disorders myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BONE MARROW DISEASE HEMATOLOGIC DISEASES MDS MYELODYSPLASTIC SYNDROME, UNCLASSIFIABLE MYELODYSPLASTIC SYNDROMES MYELOPROLIFERATIVE NEOPLASM

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.